Drug intelligence / Profile preview

VYR-104

Development stage: Preclinical
Lead developer: Vyripharm International
Modality: Hydrogel Systems → Drug Delivery Systems

Overview

VYR-104 is an investigational therapeutic candidate being developed by Vyripharm International for the treatment of Post-Traumatic Stress Disorder (PTSD). The program utilizes a specialized hydrogel drug delivery system designed to optimize the release and bioavailability of its active components. As of 2021, VYR-104 was in the IND-enabling stage of development, representing a preclinical phase focused on gathering the necessary safety and efficacy data required for an Investigational New Drug application.

Beyond the preview

Go deeper on VYR-104.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on VYR-104.

Explore the full profile